296 related articles for article (PubMed ID: 25212675)
21. T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia.
How J; Slade M; Vu K; DiPersio JF; Westervelt P; Uy GL; Abboud CN; Vij R; Schroeder MA; Fehniger TA; Romee R
Biol Blood Marrow Transplant; 2017 Apr; 23(4):648-653. PubMed ID: 28087457
[TBL] [Abstract][Full Text] [Related]
22. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
23. Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.
Yamasaki S; Yoshimoto G; Ogawa R; Aoki K; Higuchi M; Harada N; Arima F; Kondo S; Matubara F; Takahashi T; Uike N; Miyamoto T; Okamura S; Akashi K;
Ann Hematol; 2015 Jul; 94(7):1159-65. PubMed ID: 25704584
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Salvatore D; Labopin M; Ruggeri A; Battipaglia G; Ghavamzadeh A; Ciceri F; Blaise D; Arcese W; Sociè G; Bourhis JH; Van Lint MT; Bruno B; Huynh A; Santarone S; Deconinck E; Mohty M; Nagler A
Haematologica; 2018 Aug; 103(8):1317-1328. PubMed ID: 29748438
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic stem cell transplantation in first complete remission.
Oran B; Weisdorf DJ
Curr Opin Hematol; 2011 Nov; 18(6):395-400. PubMed ID: 21912256
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century.
Yanada M; Takami A; Yamasaki S; Arai Y; Konuma T; Uchida N; Najima Y; Fukuda T; Tanaka M; Ozawa Y; Ikegame K; Takanashi M; Ichinohe T; Okamoto S; Atsuta Y; Yano S
Ann Hematol; 2020 Jun; 99(6):1351-1360. PubMed ID: 32363416
[TBL] [Abstract][Full Text] [Related]
28. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.
Gyurkocza B; Lazarus HM; Giralt S
Bone Marrow Transplant; 2017 Aug; 52(8):1083-1090. PubMed ID: 28244979
[TBL] [Abstract][Full Text] [Related]
31. New approaches in allogenic transplantation in AML.
Pei X; Huang X
Semin Hematol; 2019 Apr; 56(2):147-154. PubMed ID: 30926091
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
33. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
34. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources.
Ballen KK; Joffe S; Brazauskas R; Wang Z; Aljurf MD; Akpek G; Dandoy C; Frangoul HA; Freytes CO; Khera N; Lazarus HM; LeMaistre CF; Mehta P; Parsons SK; Szwajcer D; Ustun C; Wood WA; Majhail NS
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1819-27. PubMed ID: 25064747
[TBL] [Abstract][Full Text] [Related]
35. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
[TBL] [Abstract][Full Text] [Related]
36. Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission.
Konuma T; Kondo T; Mizuno S; Doki N; Aoki J; Fukuda T; Tanaka M; Sawa M; Katayama Y; Uchida N; Ozawa Y; Morishige S; Matsuoka KI; Ichinohe T; Onizuka M; Kanda J; Atsuta Y; Yanada M;
Biol Blood Marrow Transplant; 2020 Mar; 26(3):463-471. PubMed ID: 31562960
[TBL] [Abstract][Full Text] [Related]
37. Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation.
Jones CV; Copelan EA
Future Oncol; 2009 May; 5(4):559-68. PubMed ID: 19450182
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
Gilleece MH; Labopin M; Savani BN; Yakoub-Agha I; Socié G; Gedde-Dahl T; Blaise D; Byrne JL; Craddock C; Cornelissen JJ; Arcese W; Forcade E; Crawley C; Polge E; Mohty M; Nagler A
Leukemia; 2020 Jan; 34(1):87-99. PubMed ID: 31363160
[TBL] [Abstract][Full Text] [Related]
39. Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.
Vu K; Manjappa S; DiPersio JF; Gao F; Westervelt P; Vij R; Stockerl-Goldstein KE; Uy GL; Abboud CN; Schroeder MA; Fehniger TA; Cashen AF; Romee R
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1425-30. PubMed ID: 25840336
[TBL] [Abstract][Full Text] [Related]
40. Reducing Mortality of Single-Unit Unrelated Cord Blood Transplantation for Relapsed Acute Myeloid Leukemia after a Previous Allogeneic Transplantation: A Real-World Retrospective Study Over the Past 19 Years in Japan.
Konuma T; Mizuno S; Harada K; Uchida N; Takahashi S; Eto T; Ota S; Kobayashi H; Katayama Y; Mori Y; Maruyama Y; Onizuka M; Yonezawa A; Kawakita T; Kimura T; Kanda Y; Fukuda T; Atsuta Y; Yanada M;
Transplant Cell Ther; 2022 Nov; 28(11):777.e1-777.e11. PubMed ID: 35964936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
